Danny Griffin

Danny Griffin has a diverse work experience spanning various roles in the biotech and pharmaceutical industries. Danny is currently a VC Fellow at BioGenerator Ventures, where they are involved in venture capital activities. In 2022, Danny became the Director of Business Development at Bond Biosciences, focusing on developing business partnerships. At Kinimmune, Inc., also in 2022, they assumed the role of Chief Scientific Officer. Prior to these positions, Danny worked at the University of Kansas as a PhRMA Foundation Postdoctoral Researcher and a Madison and Lila Self Graduate Fellow, where they conducted research on immunotherapy efficacy and designed antigen delivery systems. Danny co-founded Exodus Biosciences in 2016 and worked there until 2021. Additionally, Danny has gained experience as a Visiting Predoctoral Researcher at the National Institutes of Health, an Undergraduate Research Assistant at Widener University, a Scientist and Research Intern at MusclePharm, Corporation, and a Quality Assurance Intern at Pentec Health.

Danny Griffin earned their Bachelor's Degree in Biomedical Engineering from Widener University, where they attended from 2012 to 2015. After completing their undergraduate education, they pursued further studies at The University of Kansas. From 2015 to 2019, Danny Griffin successfully obtained a Doctor of Philosophy (Ph.D.) in Bioengineering.